Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (37)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  2. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

  3. Recommendations for quantitative cerebral perfusion MRI using multi-timepoint arterial spin labeling: Acquisition, quantification, and clinical applications

    Magnetic Resonance in Medicine, Vol. 92, Núm. 2, pp. 469-495

2023

  1. Arterial Spin Labeled MRI for Quantitative Non-Contrast Perfusion Measurement of the Kidneys

    Advanced Clinical MRI of the Kidney: Methods and Protocols (Springer International Publishing), pp. 299-315

  2. Mechanical Thrombectomy Global Access for Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study

    Circulation, Vol. 147, Núm. 16, pp. 1208-1220

  3. Update on state-of-the-art for arterial spin labeling (ASL) human perfusion imaging outside of the brain

    Magnetic Resonance in Medicine, Vol. 89, Núm. 5, pp. 1754-1776

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  2. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 11, pp. 491.e11-491.e19

  3. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  4. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  5. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

  6. Recent Technical Developments in ASL: A Review of the State of the Art

    Magnetic Resonance in Medicine, Vol. 88, Núm. 5, pp. 2021-2042

2021

  1. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

    Hepatology Communications, Vol. 5, Núm. 3, pp. 538-547

  2. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  3. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  5. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Leukemia, Vol. 35, Núm. 6, pp. 1722-1731

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. Consensus-based technical recommendations for clinical translation of renal ASL MRI

    Magnetic Resonance Materials in Physics, Biology and Medicine, Vol. 33, Núm. 1, pp. 141-161

  3. Technical recommendations for clinical translation of renal MRI: a consensus project of the Cooperation in Science and Technology Action PARENCHIMA

    Magnetic Resonance Materials in Physics, Biology and Medicine, Vol. 33, Núm. 1, pp. 131-140